In a rat model of reserpine induced fibromyalgia, intraperitoneal administration of the P2X7 purinergic receptor antagonist, Brilliant Blue G (BBG) at 50 mg/kg for 7-days, attenuated pain behavior and it prevented NLRP3 inflammasome activation and consequently inhibited the release of the pro-inflammatory cytokines IL-1β and IL-18 (D'Amico et al. 2021). Here, NLRP3 is linked to fibromyalgia.